CLYBL and B-cell chronic lymphocytic leukemia: However, the first phase III randomised study in this important clinical scenario emerged only in 2014 and, unsurprisingly, again from the German CLL Study Group: the CLL14 trial compared chlorambucil (CLB) monotherapy with rituximab + chlorambucil (R-CLB) and obinutuzumab (a second-generation glycosylated anti-CD20 antibody with enhanced antibody-dependent cellular cytotoxicity) + chlorambucil (G-CLB).